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Artemether is co-administered with lumefantrine as part of a ﬁxed-dose combination therapy for malaria
in both adult and pediatric patients. However, artemether exposure is higher in younger infants
(1-3 months) with a lower body weight (<5 kg) as compared to older infants (3-6 months) with a higher
body weight (5 to <10 kg), children, and adults. In contrast, lumefantrine exposure is similar in all age
groups. This article describes the clinically observed artemether exposure data in pediatric populations
across various age groups (1 month to 12 years) and body weights (<5 or 5 kg) using physiologically
based pharmacokinetic (PBPK) mechanistic models. A PBPK model was developed using artemether
physicochemical, biopharmaceutic, and metabolic properties together with known enzyme ontogeny
and pediatric physiology. The model was veriﬁed using clinical data from adult patients after multiple
doses of oral artemether, and was then applied to simulate the exposure in children and infants. The
simulated PBPK concentration-time proﬁles captured observed clinical data. Consistent with the clinical
data, the PBPK model simulations indicated a higher artemether exposure for younger infants with lower
body weight. A PBPK model developed for artemether reliably described the clinical data from adult and
pediatric patients.
© 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Introduction
An estimated 214 million malaria cases occurred globally in
2015, causing approximately 440,000 deaths.1 Most of the malaria
mortality was reported in sub-Saharan Africa and affected children
<5 years of age.1 Notably, young children in stable transmission
areas endure the greatest malarial morbidity and mortality
burden.
Artemether (20 mg)/lumefantrine (120 mg) (Riamet®/Coartem®)
was the ﬁrst approved co-formulated artemisinin combination
therapy (ACT) for the treatment of uncomplicated Plasmodium
falciparum malaria and mixed plasmodial infections including
P falciparum. It is approved for use in adults, children, and infantsncentration-time curve; Cmax,
450; fmCYP3A4, fraction of
based pharmacokinetics; PK,
1 862 778 9244; Fax: þ 1 973
Heimbach).
®. Published by Elsevier Inc. All rigwith a body weight 5 kg. However, ACT has not been approved for
use in infants <5 kg of body weight. Recently, in a ﬁrst ACT clinical
trial in infants <5 kg, the mean artemether concentrations were
reported to be 2- to 3-fold greater than those in infants and children
5 kg.2 Consistently higher artemether exposure in infants <5 kg
was not considered safe to recommend dosing artemether-
lumefantrine in this population.2
Based on its biopharmaceutic properties, artemether has been
classiﬁed as a class II drug according to the biopharmaceutics drug
disposition classiﬁcation system,3 signifying overall low aqueous
solubility with moderate to high permeability and metabolism
as the main route of elimination. Artemether’s metabolism is
mediated by CYP3A4 and CYP2B64; both enzymes have been
reported to show age-dependent expression and maturation below
5years of age.5 Thus, immatureCYP3A andCYP2B6hepatic enzymes
in infants and neonates can lead to lower artemether clearance and
higher exposure as observed in 1- to 3-month-old infants.
Predicting pharmacokinetics (PK) in pediatric patients is impor-
tant for drug development, especially in the ﬁrst 2 years of life due to
age-dependent changes in ontogeny of organ maturation and
blood ﬂow parameters, transport mechanisms, drug eliminationhts reserved.
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diatric populations or adults, novel physiologically based pharma-
cokinetic (PBPK) modeling methods have been developed which
incorporate physiological functions including unique age-
dependent maturation pattern of metabolic enzymes and trans-
porters. Thus, in contrast to the conventional allometric scaling
methods, PBPK models can account for the ontogeny and the age-
related changes in organ development and function, and thereby
provide more reliable prediction of concentration-time proﬁles
across different age groups including pediatric populations.7 This
can prospectively guide dose selection and study designs for pedi-
atric trials.8 A 2015 public workshop organized by the United States
Food and Drug Administration, entitled “Application of
Physiologically-Based Pharmacokinetic (PBPK) Modeling to Support
Dose Selection,” highlighted recent advances of PBPK modeling in
regulatory submissions. PBPK models have been highly encouraged
as they incorporate physiological factors such as age-dependent
changes in absorption and metabolism.9
The objective of the current data modeling was to demonstrate
predictability of the pediatric exposure of artemether in various age
groups using a novel PBPK model. This was accomplished by ﬁrst
developing and verifying a PBPK model using observed adult
clinical data after oral artemether administration,10 followed by
simulating artemether exposure in children and infants using the
PBPK model and comparing the results with observed clinical data.
Data for adults were obtained from an in-house study (data on ﬁle),
while data for children5 kg were obtained from Abdulla et al. and
Djimde et al.11,12 and data for infants <5 kg from Tiono et al.2
Clearance and volume were modeled using both novel PBPK and
conventional allometric methods13 for comparative purposes. Only
artemether PBPK modeling was considered in order to better
understand the previously reported differences in exposure
between infants and children/adults2 using PBPK modeling;
lumefantrine exposure was not affected by age.
Methods
Modeling Software
PBPK simulations were performed using the Simcyp® simulator
(Version 14 Release 1, Simcyp Limited, Shefﬁeld, UK) run on aFigure 1. General workﬂow for PBPK modeling to simulate druLenovo computer platform with Intel® Core i5 processor. The
simulations for virtual pediatric populations were run using the
integrated Simcyp pediatric module.Modeling Strategy for Predicting Pharmacokinetics in Various Age
Groups
The following 8 steps encompassed the framework for the
development and application of the artemether PBPK model
(Fig. 1): (a) adult PBPK model development using artemether
physicochemical and biopharmaceutic properties; (b) intrinsic
clearance (CLint) estimations for the main drug metabolizing
enzymes (CYP3A4 and CYP2B6) derived from the in vivo oral
clearance, (c) scaling of steady-state volume of distribution (Vss)
observed in various age groups (adult to pediatric patients); (d)
incorporation of oral absorption parameters (ka) estimated from
adult PK data; (e) veriﬁcation of the adult PBPK model using a
different observed dataset from an adult clinical study; (f) simu-
lation of observed artemether exposure in the pediatric population
(children, infants) using the pediatric module within Simcyp and
considering the differences in physiology, oral absorption kinetics,
and ontogeny of drug metabolizing enzymes; (g) pediatric PBPK
simulations compared against observed infant data, including
concentrations observed in infants <3 months old and <5 kg of
body weight; and (h) comparison of CL, maximal plasma concen-
tration (Cmax), and area under the plasma concentration-time
curve (AUC) parameters using PBPK and allometric scaling with
age-dependent exponents. The trial protocol was previously
described.2Construction of the PBPK Model for Adults
The PBPK model was developed and veriﬁed using observed
adult data. A combined14 “bottom-up”4,15-17 and “top-down”18,19
approach was applied. The Simcyp input parameters are summa-
rized in Table 1. Simcyp was employed for all simulations, and the
default pediatric module was used. Typically, 10 trials of 10
healthy subjects each (i.e., a total of 100 subjects) were run and
the proportion of female subjects was set at 0.5. The simulated
AUC and Cmax were expressed as mean values.g exposure in different age groups of children and infants.
Table 1
Human PBPK Model: Physicochemical, Biopharmaceutic, and ADME Input Parameters
ART Parameter Value Comment or Reference
Molecular weight (g/mol) 298 Experimental data
Log P 3.28 Measured value (data on ﬁle)
pKa e Neutral (none)
B/P 0.8 Colussi et al.16
Fraction unbound in plasma 0.046 Experimental data (in house)
Absorption First-Order Absorption Model
Fa 1 High fraction of dose absorbed as reported by Ezzet et al.18 Experimental
data via ADMET predictor.18
ka (h1) 0.37 Estimated ka is not likely impacted by age (Bonner et al.15).
Effective human permeability (104 cm/s) 4.27 Experimental data from ADMET predictor17
fu,gut 0.046 Same as measured fup
Qgut (L/h) 12.6 Simcyp predicted
Distribution Parameters for Adult and Pediatric Model Minimal PBPK Model
Vss (L/kg) 6.75 Estimated from Salman et al.19
VSAC (L/kg) 5.72
Inter-compartmental clearance, Q (L/h) 18.6
Elimination Enzyme Kinetics
Oral CL/F (L/h) 102 Estimates from Salman et al.19 F is ~0.4 or 40%
Intrinsic clearance, CLint (mL/min/pmol of isoform) CLint was estimated using the Simcyp retrograde model from CL/F. This
represents an ~6-fold greater CLint for CYP2B6 than CYP3A4. A 6-fold
higher Vmax/KM for CYP2B6 relative to CYP3A4 has been reported by
Honda et al.4
CYP3A4 2.27 (fumic ¼ 1)
CYP2B6 12.2 (fumic ¼ 1)
Fraction of ART metabolized 1
Fraction of ART eliminated unchanged ~0
Fraction of ART metabolized by CYP3A4 of total CL fmcyp
CYP3A4
0.7 Adult patients: Simcyp predicted; pediatric patients: age dependent
Fraction of ART metabolized by CYP2B6 of total CL fmcyp
CYP2B6
0.3 Adult patients: Simcyp predicted; pediatric patients: age dependent
ADME, absorption, distribution, metabolism, excretion; ART, artemether.
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The ﬁrst-order oral absorption rate constant (ka) was estimated
by ﬁtting the 2-compartment model with ﬁrst-order oral absorp-
tion to the observed concentration-time proﬁle from adult malaria
patients who took minimal to standard food (data on ﬁle). No
further adjustments were made to the absorption parameter and a
minimal PBPKwas used. Fwas estimated to be 1 from the published
report17 and a light meal ACATmodel within GastroPlus® in malaria
patients who took minimal to standard food (data on ﬁle).
Estimation of Systemic PK Parameters From Adult Data
The PK parameter ka was estimated from a population PK
analysis using full proﬁles of 42 patients with 15 years of age.18
CL/F and Vss were determined by population PK analysis based
on data from children with uncomplicated malaria.19 A minimal
PBPK model in Simcyp simulator was used to account for the
distribution of artemether. The estimate for Vss in adult patients
with malaria was obtained from observed data in children with
malaria following oral administration of 1.7mg/kg artemether. The
Vss was deﬁned in L/kg in order to account for differences in body
weight of the simulated population. A single adjusting compart-
ment (SAC) was used to adjust the volume of distribution. The
estimates of Vss (6.75 L/kg), VSAC (5.72 L/kg), and inter-
compartmental clearance (18.6 L/h) were obtained from popula-
tion PK analysis in children with malaria following administration
of Coartem (1.7 and 10 mg/kg of body weight for artemether and
lumefantrine, respectively).
Estimation of Intrinsic Clearance and Enzyme Ontogeny
Honda et al.4 reported the intrinsic clearance of artemether via
demethylation by CYP2B6 to be 6-fold greater than that of CYP3A4.
The intrinsic clearances due to each CYP2B6 and CYP3A4 wereestimated “top-down” from the observed artemether in vivo oral
clearance (102 L/h) using the in-built retrogrademodel. The relative
contributions (%) of CYP2B6 and CYP3A4 were adjusted to match
observed in vitro intrinsic clearance differences (Table 1). The
age-related maturation pattern of enzymes in the pediatric module
of Simcyp simulator allows for the prediction of hepatic clearance
across different age groups in the pediatric population by taking
into account the ontogeny of CYP3A4 and CYP2B6 and physiological
differences such as hepatic blood ﬂow and liver volume.6 Studies
have reported minimal or no quantiﬁable concentrations of
artemether in urine, thus renal elimination is insigniﬁcant (data on
ﬁle) and the renal clearance pathway was not incorporated into the
clearance projection.19
PBPK Model Veriﬁcation in Adults Using Observed Clinical Data
The developed PBPK model was veriﬁed using clinical data
obtained in adult patients following multiple doses of oral arte-
mether (Table 2) (dose: 80 mg per dosing interval; dosing interval:
0, 8, 24, and 48 h; plasma sampling time points: 0, 4, 8, 12, 16, and
24 h after the ﬁrst dose; N ¼ 218). The simulations were performed
following multiple oral administration of artemether 80 mg/dose.
The characteristics of the adult populationwere the default healthy
volunteer population; all men, age range between 20 and 50 years;
and drug administered under fed condition. The selection of these
virtual population characteristics and the dose for the simulation
were based on the study details from the clinical study in adults.
Ten trials of 10 healthy subjects (i.e., 100 subjects) were run, as
recommended,20 and the simulated AUC and Cmax were expressed
as mean values. The simulated mean PK proﬁle (with 5th and 95th
percentile curves) was obtained. The PBPK simulated proﬁle was
then compared to the observed PK data.
Table 2
Artemether PBPK Simulated and Observed Exposure Parameters in Adult and Pediatric Patients
Population Age Band Dosea
(mg/dose)
MF Predicted Artemether Exposure
Cmax Mean
[observed mean
± standard deviation]b
(ng/mL)
AUC
(ng$h/mL)
Fold AUC
Increase
Over Adultc
AUC/Dose
(ng$h/mL)/mg
AUC/Dose
(ng$h/mL)/
(mg/kg body
weight)
Adults 20-50 years, N ¼ 12 80d 139 [160 ± 143] 909b e 11.4 795
20-50 years, N ¼ 0 20e 1 34.8 227 1 11.4 795
Children 5-12 year (15 to <25 kg of
body weight), N ¼ 64
40f,g 0.99 176 [143 ± 121] 1076b e 26.9 549
2-5 years (5 to <15 kg of
body weight), N ¼ 62
20f,g 0.90 140 [132 ± 130] 989b 3.5 49.5 638
Older infants 6 months to 2 years (5 to
<15 kg of body weight),
N ¼ 37
20f,g 0.73 206 [294 ± 223] 1974b 8.7 98.7 1034
3-6 months (5 to <10 kg of
body weight), N ¼ 3
20f,g 0.33 453 [572 ± 81.3] 4303b 19.0 215 1442
Younger
infants
1-3 months (5 to 15 kg of
body weight), N ¼ 0)
20e 0.20 717 6712b 29.6 336 1956
1-3 months (<5 kg of body
weight), N ¼ 10
20f,h 755 [621 ± 299] 9828b 43.3 491 2143
MF, estimated hepatic enzyme maturation factor, estimated as (fmCYP2B6 maturity of adult fraction)þ (fmCYP3A4maturity of adult fraction), adult levels deﬁned as 1 or
100%; N, number of subjects with observed plasma concentrations from published report by Tiono et al.2
a Artemether/lumefantrine dose was 80 mg/480 mg for adults, 40 mg/240 mg for pediatric patients with a body weight 15 to <25 kg, and 20 mg/120 mg for pediatric
patients with a body weight <15 kg. In adults, standard Coartem tablets were used. In children both dispersible tablets2,11 and crushed standard tablets11 were used which
yielded similar exposure.21
b Data are pharmacokinetics on day 1. Observed AUC data are not available due to sparse pharmacokinetic sampling in pediatric patients.
c Fold increase in AUC after a single 20 mg dose.
d Observed PK data from unpublished internal data; intact tablets were used.
e No observed data.
f Observed PK data from published report by Tiono et al.2
g Both dispersible and crushed standard tablets were used by Abdulla et al.11
h Dispersible tablet was used by Tiono et al.2
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To establish the pediatric PBPK model, the default Simcyp
pediatric module was used. Age-dependent characteristics for
metabolism and elimination, along with the physicochemical
properties of artemether, were considered. The age-related physi-
ological characteristics for the pediatric population and the
ontogeny proﬁle were fully integrated into the pediatric Simcyp
simulator module. Clearance values, expressed as intrinsic clear-
ances of individual enzymes, incorporated the inﬂuence of
age-related maturation of enzymes (ontogeny) in the gut and liver.
Salman et al.19 reported on the population PK estimates for arte-
mether followingadministrationofCoartem(1.7and10mg/kgofbody
weight forartemetherand lumefantrine, respectively) inchildren5-10
years old (14). The estimates of Vss, VSAC, and inter-compartmental
clearance in the pediatric PBPK model (Table 1) were obtained from
an artemether 2-compartment population PK model.19
The pediatric clinical study was conducted in 899 patients with
an age range of 108 days to 12 yearswith a bodyweight5 kg.11 The
doses were administered at speciﬁed times (0, 8, 24, 36, 48, and
60 h) based on body weight: 1 tablet of artemether-lumefantrine
(20 mg of artemether and 120 mg of lumefantrine) per dose for
patients weighing 5 to <15 kg, 2 tablets per dose for patients
weighing 15 to <25 kg, and 3 tablets per dose for patients weighing
25 to <35 kg. Both dispersible and crushed tablets were adminis-
tered. The consumption of some food or drink (e.g., breast milk,
broth, or sweetened condensed milk) was recommended after the
intake of medication to increase absorption.11 The blood samples
were collected at 1 and 2 h after the ﬁrst dose to estimate the Cmax
associated with artemether.12
A subsequent clinical study was conducted in infants 1 month to
1 year old with a body weight <5 kg.2 Patients received 1 tablet of
artemether-lumefantrine (20 mg of artemether and 120 mg oflumefantrine) twice daily for 3 consecutive days. Dispersible tablets
were used. Limited artemether PK data (2-3 time points) could be
obtained in this population, because of the restrictions for both the
number and total volume of blood samples.2,12 The consumption of
food or drink (mother's or formula milk) was recommended after
dose to enhance lumefantrine absorption.
Based on a study in healthy subjects, artemether has a little to no
more than a 2-fold increase in systemic exposure when adminis-
tered with high fat food. This is in contrast to lumefantrine whose
bioavailability is markedly increased with high fat meals (up to
16-fold). Adult patients were recommended to take standard food
or drink (e.g., milk, formula, pudding, broth, and porridge)
(Coartem tablets prescribing information). Similarly, pediatric
patients were recommended to consume limited amount of food
(e.g., pancake) or some liquid meal (e.g., breast milk, broth, or
sweetened condensed milk).2,11
Simulation of Artemether PK Proﬁles in Children 2-12 Years
The PK proﬁles in pediatric populations 2 to <5 years and 5-12
years were predicted following the aforementioned multiple
dosing scheme of oral artemether. Ten trials of 10 healthy subjects
aged 2-12 years each were run and the simulated AUC and Cmax
were expressed as mean values. The proportion of females was set
at 0.5. To relate the simulated PK proﬁle to the observed data,
individuals within a body weight range corresponding to an
artemether dose (20 mg/dose for 5 to <15 kg body weight, 40 mg/
dose for 15 to <25 kg, and 60 mg/dose for 25 to <35 kg) were
selected from the simulated population to obtain the mean simu-
lated concentration-time proﬁle (with 5th and 95th percentile
curves). The simulated PK proﬁles generated for a speciﬁed dose
were veriﬁed using the observed data matched with the age group
and body weight range-based dose.
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To investigate the effect of bodyweight on artemether exposure,
the simulated virtual pediatric population with an age range of 28
days to 3 months was sorted into 2 different body weight groups of
<5 and5 kg. The rate and extent of exposure were estimated from
the simulated proﬁles to investigate the effect of body weight on
the exposure for infants in the same age range. The simulated mean
concentration-time proﬁles (with 5th and 95th percentile curves)
for the group with a body weight <5 kg were compared with the
observed concentrations to ascertain the predictability of the
model. However, no clinical data were available for 28-day-old to
3-month-old infants with a body weight 5 kg. Hence, the simu-
lated mean concentration-time proﬁles (with 5th and 95th
percentile curves) for 3- to 6-month-old infants with a body weight
5-10 kg were compared to the observed concentrations.
In addition, the simulation in infants 6 months to 2 years (body
weights 5 to <15 kg) was performed following multiple oral
administration of artemether 20 mg/dose using the pediatric
module within Simcyp to describe the limited data available.2 As
stated previously, the dose for simulation of PK proﬁle in the
pediatric population was based on dosing in the clinical study.
Comparison of Clearance Values Between PBPK and Allometry Using
Age-Dependent Exponents
Allometry is still a recommended method for pediatric patients
>2 years of age9 and different age-based exponents have been
recommended.13,22 The following equation relates the parameter of
interest to the body weight:
Y ¼ a body weightb [1]
where Y is the parameter of interest, a is the coefﬁcient, and b is the
exponent.
Considering the proportional relationship between the param-
eter of interest and the body weight, the clearance in adults can be
scaled to children:
CLpediatric ¼ CLadult 

Body weightpediatric
Body weightadult
exponent
[2]Figure 2. Construction and qualiﬁcation of the adult PBPK model. Simulated versus observed
the mean simulated plasma concentration of 100 subjects (10 trials of 10 subjects in each tr
squares represent the mean observed concentrations and vertical bars the standard deviati
after multiple doses of oral artemether 80 mg. (b) The solid squares represent the mean
concentrations in adult malaria patients (N ¼ 218) from a clinical study after multiple oralCL refers to the systemic clearance and the subscript denotes
pediatric or adult patients. CL was estimated from weight-based
allometric scaling with various recommended exponents (0.75 for
children older than 5 years, 0.9 for children 2-5 years, 1.0 for infants
3 months to 2 years, and 1.2 for infants 1-3 months) for different
pediatric age groups.22 As the exponent increases from 0.75 to 1.2,
the pediatric CL decreases, with infants showing the lowest CL and
highest AUC.22,23 The mean body weight in each age group was
obtained from the trial demographics related to the simulated
population, and the systemic clearance was scaled from adult
clearance. The predicted clearance based on the allometry in each
age group with various exponents was then compared with the
predicted clearance from the PBPK model using the Simcyp
pediatric module.Results
Development and Qualiﬁcation of Artemether PBPK Model for Adults
The PBPK model was parameterized with artemether physi-
ochemical and biopharmaceutic properties (Table 1). The esti-
mates of CL, Vss, VSAC, and ka were obtained from analyses
performed using PK data from patients with malaria (Table 1) who
took limited food during the clinical trial. The ﬁrst-order absorp-
tion rate constant (ka) of 0.37 per hour (CV of 63%) was estimated
“top-down” and was considered to be independent of age.15 A
detailed gut absorption model was not included as artemether
systemic exposure was not altered in malaria patients who took
limited food during clinical trials. The estimate of oral clearance
(102 L/h) was incorporated in the PBPK model in the form of
intrinsic clearances of CYP2B6 and CYP3A4 using retrograde model
in Simcyp. The intrinsic clearance of CYP2B6 (12.2 mL/min/pmol)
was observed to be 6-fold greater than that of CYP3A4 (2.27 mL/
min/pmol; Table 1). This was similar to the experimentally
observed ratio for intrinsic clearances of CYP2B6 and CYP3A4. The
fraction of artemether metabolized by cytochrome P450 enzymes
as part of the total CL values, fmcyp, was 0.70 for CYP3A4 and 0.30
for CYP2B6 from the Simcyp prediction. Using inputs from Table 1,
the PBPK model can well simulate the observed plasma concen-
tration proﬁles from 12 malaria adult patients after 2 doses of
80 mg artemether (Fig. 2a).mean plasma concentrations of artemether in patients. The solid black line represents
ial) with 5th and 95th percentile proﬁle represented by the dashed lines. (a) The solid
on of the mean concentrations in adult malaria patients (N ¼ 12) from a clinical study
observed concentrations and the vertical bars are standard deviation of the mean
doses of artemether 80 mg.18
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the clinical data obtained after administration of multiple doses
of oral artemether.18 The observed data suggested high inter-
individual variability in systemic concentrations. In adults, with
the exception of a few observations, the simulated mean proﬁles
and the 5th and 95th percentile curves can capture the observed PK
data for all individuals obtained after administration of multiple
doses of oral artemether, 80 mg per dose (Fig. 2b).PBPK Simulation for Adults and Veriﬁcation for Pediatric Patients
1 Month to 12 Years
The mean PK proﬁles with 5th and 95th percentile curves
simulated from the PBPK model captured the observed data in
adults (Fig. 2), children 5-12 years (Fig. 3a) children 2-5 years
(Fig. 3b), infants 6 months to 2 years (Fig. 4a), infants 3-6 months
with a body weight5 and <10 kg (Fig. 4b), and infants 1-3 months
with a body weight <5 kg (Fig. 4c). The simulated rate (Cmax) and
extent of exposure (AUC) increased with decreased age (Table 2),
which correlate well with the corresponding clinical exposure data
in each tested age group. The observed data in the ﬁgures, as
denoted by the solid dots, indicated high inter-individual variability
in the exposure of artemether, consistent with the observed data.
Artemether PK parameters have been reported to exhibit high
inter-individual variability.18,24 The differences in PK among
individuals could be partially attributed to environmental and
genetic factors. The simulation Cmax (755 ng/mL) captured the
observed exposure (Cmax 621 ± 299 ng/mL) in infants 1-3 months
and <5 kg of body weight after oral administration of artemether
(Fig. 4c).2 The effect of body weight on the exposure was investi-
gated in this age group from the simulated PK proﬁle. The
predicted AUC (9828 ng$h/mL) of artemether for infants <5 kg of
body weight was ~1.3-fold greater than that (7246 ng$h/mL) in
infants with a body weight 5 kg in the same age group (Table 2).
The lower artemether exposure in infants with a body weight
5 kg (mean body weight 5.6 kg) was caused by lower body weight
normalized dose (3.57 mg/kg) than that of infants with a body
weight <5 kg (4.76 mg/kg). The predicted AUC normalized by dose
(mg/kg) in 1- to 3-month-old infants with body weight <5 or5 kg
was similar (2143 vs. 1956 (ng$h/mL)/(mg/kg)). Furthermore, the
predicted CL (0.25 L/h/kg) of artemether for infants <5 kg of body
weight was slightly lower than that (0.27 L/h/kg) in infants with aFigure 3. Simulation of the mean plasma concentration of artemether in children 2-12 year
subjects (10 trials of 10 subjects in each trial) with 5th and 95th percentile proﬁle represen
(a) Plasma concentration-time proﬁle of artemether in children 5 to 12 years after mu
concentration-time proﬁle of artemether in children 2-5 years after multiple doses of oralbody weight 5 kg in the same age group (Fig. 5b). It indicated that
body weight only slightly affects CL in 1- to 3-month-old infants.
Because the body weight of all the infants 1-3 months in the
clinical trial was <5 kg,2 no observed artemether exposure data
were available for infants 1-3 months with a body weight 5 kg.
The simulated Cmax (453 ng/mL) was comparable to the observed
Cmax (572 ± 81.3 ng/mL) from infants 3-6 months with a body
weight 5 and <10 kg (Table 2). The predicted CL for infants 3-6
months was 0.37 L/h/kg (Fig. 5b), which was ~30% higher than the
predicted CL (0.27 L/h/kg; Fig. 5b) for infants 1-3 months with a
body weight 5 kg.
Nearly a 1.7-fold increase in exposure was predicted in infants
1-3 months (5 kg) compared to the age group of 3-6 months (5,
<15 kg). The predicted CL for infants 3-6 months and5 kg of body
weight was 0.37 L/h/kg, which was ~1.4-fold greater than the
predicted CL (0.27 L/h/kg) for infants 1-3 months and5 kg of body
weight, suggesting the role of physiological differences and enzyme
maturation in the exposure of artemether. The higher liver enzyme
level for 3- to 6-month-old infants 5 kg of body weight compared
to 1- to 3-month old infants5 kg of bodyweightmight explain the
lower exposure in the former group.5Comparison of Clearance From PBPK Model and Modiﬁed Allometric
Approach
The clearances in pediatric patients predicted from adult
clearances using weight-based allometry with various exponents
were compared with the PBPK model-predicted clearance in each
age group (Fig. 5a). The exponents that predicted systemic
clearance closest to the PBPK model-predicted CL for each age
group are as follows: 1.2 for infants <6 months; 1.0 for infants 6
months to 2 years; 0.9 for children 2-5 years; and 0.67 for children
5-12 years.Discussion
Pediatric drug research and development is associated with
challenges in obtaining adequate drug exposure data across
various age groups in order to optimize the therapeutic regimen
for the pediatric population. Until recently, pediatric doses were
typically based on body weight or body surface area scaling from
adults.10 These conventional scaling methods have signiﬁcants old. The solid black line represents the mean simulated plasma concentration of 100
ted by the dashed lines. The observed concentrations are represented as solid squares.
ltiple doses of oral artemether 40 mg (body weight 15 and <25 kg). (b) Plasma
artemether 20 mg (body weight 5 and <15 kg).
Figure 4. Prediction of mean plasma concentration of artemether in infants 1 month to 2 years. The solid black line represents the mean simulated plasma concentration of 100
subjects (10 trials of 10 subjects in each trial) with 5th and 95th percentile proﬁle represented by the dashed lines. The observed concentrations are represented as solid squares.
(a) Mean plasma concentration of artemether over time in infants 6 months to 2 years (body weight 5 and <15 kg) after multiple doses of oral artemether 20 mg. (b) Mean
artemether plasma concentration-time proﬁle in infants 3-6 months (body weight 5 and <10 kg) after multiple doses of oral artemether 20 mg. (c) Mean plasma concentration of
artemether over time in infants 1-3 months (body weight <5 kg) after multiple doses of oral artemether 20 mg.
W. Lin et al. / Journal of Pharmaceutical Sciences 105 (2016) 3205-3213 3211limitations such as lack of consideration of ontogeny and lack of
accountability of elimination and transport mechanisms.8 In
recent years, these gaps have been addressed with the evolution
of PBPK modeling. Regulatory agencies now strongly encourageFigure 5. (a) Simulated body weight normalized PBPK model-predicted systemic plasma cle
clearance (considering ontogeny and bioavailability) was compared to the systemic cleara
exponents. The Mahmood’s exponents that predicted systemic clearance most similar to th
6 months to 2 years, 0.9 for children 2-5 years, and 0.67 for children 5-12 years. By comparis
different age groups: 1.2 for infants 3 months, 1.0 for infants >3 months to 2 years, 0.9 for
normalized clearance (L/h/kg) which described observed oral dosing data for pediatric popthe use of PBPK models for predicting exposure in pediatric pa-
tients before initiating the clinical trials.9,25 The framework of
learning, conﬁrming, applying, and predicting pediatric PKs was
applied10 and the PBPK model development and qualiﬁcationarance (L/h/kg) for artemether across different age groups. The PBPK model-predicted
nce for pediatric patients scaled from the systemic clearance in adults with varying
ose from the PBPK models were as follows: 1.2 for infants <6 months, 1.0 for infants
on, Mahmood had proposed different exponents for clearance-based dose selection for
>2 years and up to 5 years, and 0.75 for 5 years.13,20 (b) The simulated body weight
ulations across different age groups and adults.
Figure 6. Pediatric enzyme ontogeny proﬁles for CYP3A4 and CYP2B6 within the PBPK
model. Above 5 years, enzyme maturation approaches adult levels.
W. Lin et al. / Journal of Pharmaceutical Sciences 105 (2016) 3205-32133212experiences gained for the artemether pediatric program were
presented in a retrospective manner.
The PBPK modeling is of distinctive value for describing
artemether exposure across populations. Only sparse artemether
PK data (2-3 ﬁxed time points for all patients) could be obtained
from younger infants due to limitations of number and volume of
blood samples. The limited data were not sufﬁcient to build a
reliable population PK model describing the shape of PK proﬁle.
Hence, a mechanistic PBPK was chosen for a reliable estimation of
the artemether PK proﬁle in infants.
Bonner et al.15 showed that age was not a signiﬁcant covariate
for gastric emptying time in pediatric patients. Instead, meal type
impacted gastric emptying based on model-based meta-analysis of
data from premature neonates to adults. In patients with malaria,
the Cmax of artemether is generally higher than that in fasted
healthy volunteers.26 Hence, the absorption parameters (ka and Fa)
in the adult PBPK model were derived from malaria patients (data
on ﬁle) who took minimal to standard food or drink. Considering
similar lower fat/calorie food administration in both adult and
pediatric patients, the utility of adult absorption parameters (ka
and Fa) in the pediatric PBPK model is reasonable. Indeed, it could
well simulate the artemether plasma concentrations at 1 and 2 h
post dose from 1-month-old infants to 12-year-old children. The
simulation results hinted that, for a drug with mild food effect, the
absorption parameters derived from adult PK data could be applied
to the pediatric PBPK model when the food type was similar
between adult and pediatric patients (Table 1).
In adults, standard Coartem tablets were used. However, in the
pediatric population, both the dispersible formulation2,11 and
crushed standard tablets11 were used. A relative bioavailability
study showed comparable exposure for dispersible tablet, intact
tablet, and crushed intact tablet.21 The overall mean Cmax for
artemether was 175 ng/mL (standard deviation 168; n ¼ 91) in the
dispersible tablet group and 211 ng/mL (standard deviation 262;
n ¼ 93) in the crushed tablet group.11 Lower difference in exposure
could be due to high variability of artemether exposure (CV%
of ~70).11 Furthermore, these data provide support for the use of
absorption parameters derived from adults with malaria who took
standard Coartem tablets in the infant and children PBPKmodel for
dispersible or crushed standard tablets.
In theory, when a constant artemether dose of 20 mg is
administered to children and adults, higher systemic exposure
(AUC or AUC/dose) is expected in patients with lower body weight
(Table 2), even when enzymes have fully matured. Incomplete
maturation of metabolic enzymes can further increase drug
exposure, especially in infants and younger children.5 Age-
dependent artemether exposures were indeed observed in the
pediatric clinical studies2 (Fig. 4 and Table 2).
A ﬁxed dose (20 mg) led to higher artemether exposure in
children compared to adults probably due to a combination of
lower body weight and lower hepatic enzyme maturity of CYP3A4
and CYP2B6 (Table 2). In infants 6 months to 2 years, CYP3A4
reaches ~50% to ~90% of the adult level and artemether 20 mg dose
is predicted to result in a ~6-fold greater Cmax and an estimated
8.7-fold greater AUC (Table 2). However, in infants 1-3 months, the
CYP3A4 expression level is only <25% that of adults. A 20 mg dose
of artemether leads to ~20-fold greater Cmax and an estimated
43-fold greater AUC (Table 2), because of lower metabolic clearance
and lower body weight (Fig. 5b).
PBPKmodeling is currently preferred over the allometric scaling
method for children <2 years old,9 because of the age-related
developmental changes. Dose selection for children below 2 years
has been extremely challenging because of the existing knowledge
gap related to absorption, distribution, and elimination of drugs.
Foissac et al.27 have shown that for the pediatric population<2 years of age, the weight-based allometric scaling overestimated
the clearance with signiﬁcant bias, and that the physiologically
based method predicted the clearance with good accuracy. To
improve allometry, Mahmood22 recognized the problem and
proposed different exponents for clearance-based dose selection
for different age groups.
Clearance values for pediatric patients scaled from adult values
using weight-based allometry with various exponents were
compared with the PBPK model-predicted clearance in each age
group. Figure 5a illustrates that the artemether PBPKmodel yielded
overall comparable CL estimates as the simple age-dependent
exponent allometric method. While these results may appear to
be complementary, PBPK models remain preferred.9 The allometric
exponents that predicted systemic clearance closest to the PBPK
model-predicted clearances in each age group are as follows: 1.2 for
neonates and infants <6 months; 1.0 for infants and children
6months to 2 years; 0.9 for children 2-5 years; and 0.67 for children
5-12 years. The suitability of an exponent of 1.2 in predicting
clearance using weight-based allometric scaling for infants
<6 months suggests the lower expression/activity of drug metab-
olizing enzymes (CYP3A4 and CYP2B6). The exponent of 1.2 for this
age range is in accordance with the proposed exponent.22 For
infants and children 6 months to 2 years, the proposed exponent of
1 was observed to be more suitable. Similar clearance predicted
from the PBPK pediatric model further suggested the maturation
phase of drug metabolizing enzymes (CYP3A4 and CYP2B6) in this
age group. The intrinsic clearance from hepatic CYP3A4 enzyme
reaches adult value at about 1.3 years.28 Taking into consideration
that the hepatic enzymes, especially CYP3A4, reach maturation
levels near 2 years of age,5 the liver size and liver blood ﬂow are the
key determinants for clearance in children older than 2 years. For
children 2-5 years, the predicted clearance with an exponent of 0.9
is closer to the PBPK predicted clearance. The hepatic CYP2B6 has a
slower maturation rate in comparison to CYP3A4, reaching the
adult maturation level by 5-10 years of age (Fig. 6). This explains the
similar predicted clearance values from the PBPK model compared
to the one predicted by the exponent of 0.9. The exponent of 0.67
for children 5-12 years resulted in higher CL than that predicted
with the exponent of 0.75, which was suggested by Mahmood. The
liver volume normalized to body weight has been reported to be
higher in younger children which can be translated to the higher
observed clearance normalized to body weight,29 considering that
enzyme expression beyond 5 years of age is similar to that in
adults. The results suggested that the conventional weight-based
W. Lin et al. / Journal of Pharmaceutical Sciences 105 (2016) 3205-3213 3213allometric scaling could be used to predict the clearance in this age
group. In addition, this further indicates that the maturation level
of drug metabolizing enzymes in children in this age group is
similar to that in adults.
The body weight normalized clearances (L/h/kg) predicted from
the PBPKmodel are presented in Figure 5b. In addition to ontogeny,
liver weight and liver blood ﬂow are also important determinants
of clearance. Higher body weight normalized clearance was
predicted in pediatric patients older than 5 years as compared to
adults (Fig. 5b). This can be explained as follows: in older children
(>5 years), ontogeny is more advanced along with a high liver
volume (normalized to body weight) compared similar to adults.
Moreover, the liver volume normalized to body weight in children
decreases with increase in age (age range 3.3-18.8 years), and older
children have lower liver volume-to-body weight ratio as
compared to younger children.29
For children 2-5 years, the clearance normalized to body weight
was not as high as for children >5 years (Fig. 5b). A possible reason
could be the slower maturation rate of the CYP2B6 enzyme, which
is as low as 60% (Fig. 6), and a lower maturation factor (Table 2).
While the CYP2B6 activity has been estimated to be complete at
birth by some authors,30 for our patients we used the default
Simcyp-derived ontogeny proﬁle for CYP2B6 where the adult
maturation level is reached above 5 years of age.5,31
When resorting to allometry, to estimate CL in the pediatric
population, the selection of suitable exponents demands caution,
especially in neonates and infants. A ﬁxed exponent of 0.75 is not
appropriate.22 Even with age-dependent exponents, allometry has
limitations as mechanistic details in drug disposition are not
included. The choice of suitable exponents might depend on the
maturation rate of major enzymes involved in the metabolism of
the drug. A PBPK modeling approach can provide a more reliable
prediction of clearance by taking into consideration the unique
maturation pattern of the drug metabolizing enzymes and the
development of organ function.
Conclusion
Amechanistic PBPKmodel for artemether was developed which
could reliably simulate the observed PK in adults, children, and
infants. The model describes the observed exposure across all age
groups of pediatric patients, including the observed higher
artemether exposure in infants <5 kg of body weight and aged
<3 months. The PBPK model was a better predictor than allometric
methods given the inﬂuence of blood ﬂow and enzyme maturation
play in clearance mechanisms.
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